Linezolid Pliva

Linezolid, the active ingredient in Linezolid Pliva, is an oxazolidinone antibiotic presented as an oral tablet for systemic use. It treats serious bacterial infections, including those caused by resistant Gram‑positive organisms, in adult patients. GNH USA supplies Linezolid Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic indicated for infections caused by susceptible bacteria. - Skin and soft tissue infections: eradicates methicillin‑resistant Staphylococcus aureus (MRSA) and other Gram‑positive pathogens in affected tissues. - Community‑acquired pneumonia: provides coverage against typical and atypical organisms, including resistant strains. - Nosocomial pneumonia: treats hospital‑acquired lower respiratory infections caused by susceptible organisms. - MRSA infections: offers an effective oral option for confirmed MRSA infections when other agents are unsuitable.

Linezolid may cause a range of adverse reactions, most of which are dose‑independent.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring during therapy. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception. - Myelosuppression: reduction in blood cell counts, especially with prolonged use. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: metabolic disturbance requiring immediate attention. - Severe thrombocytopenia: markedly low platelet counts. - Optic neuritis: visual disturbances and potential vision loss. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: rash, fever, or anaphylaxis.

Before prescribing Linezolid, clinicians should consider several safety aspects. - Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: assess liver enzymes and use with caution. - Hematologic monitoring: perform regular complete blood counts during prolonged treatment. - Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. - Pregnancy and lactation: evaluate risk‑benefit ratio; limited data available. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Linezolid interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: may precipitate serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis. - Tyramine‑rich foods: can exacerbate hypertensive reactions when combined with MAOIs.

Moderate Interactions (Monitor Closely): - Rifampicin: may reduce linezolid plasma concentrations. - Warfarin: potential for enhanced anticoagulant effect; monitor INR. - Ethanol: may increase the risk of hypotension. - CNS depressants: additive sedation possible. - Antacids containing magnesium or aluminum: may affect absorption; separate administration times.